Documents
-
- Full text
- closed access
-
- Download
- Title page_Table of contents
- open access
-
- Download
- Chapter 1 Introduction
- open access
-
- Download
- Chapter 2
- open access
- Full text at publishers site
-
- Chapter 3
- closed access
- Full text at publishers site
-
- Download
- Chapter 5
- open access
- Full text at publishers site
-
- Download
- Chapter 7 Summary and general discussion
- open access
-
- Download
- Propositions
- open access
In Collections
This item can be found in the following collections:
Adjuvant-conjugated peptide vaccines for immunotherapy of cancer
Immunotherapy of cancer has established itself in recent years as a promising novel approach to treat cancer patients. One of the experimental approaches is based on therapeutic vaccination. We have previously developed vaccines consisting of synthetic long peptides (SLP) which successfully eradicated premalignant lesions in 50% of patients. To further improve these vaccines, a Toll-like receptor ligand (TLR-L) was conjugated to SLP which enables targeting of the SLP to relevant antigen-presenting cells while concomitantly activating these cells. In fact, the research described in this thesis shows that TLR-L SLP conjugates induce enhanced antitumor immunity. Furthermore, optimization of the TLR-L led to even furher improved antitumor responses in mice. Using human cancer patient-derived lymph node cells, we show that lymph node-derived T cells are favorably activated by the TLR-L SLP conjugates. Finally, we combine multiple...
Show moreImmunotherapy of cancer has established itself in recent years as a promising novel approach to treat cancer patients. One of the experimental approaches is based on therapeutic vaccination. We have previously developed vaccines consisting of synthetic long peptides (SLP) which successfully eradicated premalignant lesions in 50% of patients. To further improve these vaccines, a Toll-like receptor ligand (TLR-L) was conjugated to SLP which enables targeting of the SLP to relevant antigen-presenting cells while concomitantly activating these cells. In fact, the research described in this thesis shows that TLR-L SLP conjugates induce enhanced antitumor immunity. Furthermore, optimization of the TLR-L led to even furher improved antitumor responses in mice. Using human cancer patient-derived lymph node cells, we show that lymph node-derived T cells are favorably activated by the TLR-L SLP conjugates. Finally, we combine multiple innate immune stimulatory agonists (TLR2-L and NOD2-L) in one molecule to establish synergistic immune activation. Overall, the research described in this thesis demonstrates the potency of TLR-L SLP conjugates as cancer vaccines, which could strongly contribute to the treatment of cancer patients.
Show less- All authors
- Zom, G.G.P.
- Editor(s)
- Zom G.G.P.
- Supervisor
- Ossendorp, F.A.; Melief, C.J.M.
- Committee
- Geluk, A.; Ovaa, H.; Toes, R.E.M.; Gruijl, T.D. de; Kooyk, Y. van
- Qualification
- Doctor (dr.)
- Awarding Institution
- Medicine , Leiden University
- Date
- 2017-10-19
- ISBN (print)
- 9789492679147
Funding
- Sponsorship
- ISA Pharmaceuticals; Greiner Bio-one